IP
IPIX.US Innovation Pharmaceuticals Inc
- Market cap
- USD 259K
- P/E
- -
- P/B
- 1.78x
- ROE
- -302.9%
- Dividend yield
- 33.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2023.
Is IPIX.US undervalued?
Graham numberThe Graham number of Innovation Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innovation Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Innovation Pharmaceuticals Inc yet.
Innovation Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It offers Brilacidin, a immunomodulatory drug candidate with anti-inflammatory and antimicrobial therapeutic applications. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorpor…
Full company profileInnovation Pharmaceuticals Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innovation Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 423K | 23.0K | 18.0K | 18.0K | 24.0K |
| Gross Profit | 0.00 | 0.00 | -420K | -406K | -413K | -371K | 423K | -378K | 18.0K | -373K | -352K |
| Operating Income | -8.04M | -13.0M | -12.7M | -15.3M | -13.9M | -6.45M | -4.64M | -9.02M | -6.92M | -172K | -3.46M |
| EBITDA | -7.75M | -12.6M | -12.2M | -14.9M | -13.5M | -6.11M | -6.02M | -8.64M | -6.54M | -172K | -3.09M |
| Net Income | -8.25M | -13.1M | -12.9M | -15.5M | -16.4M | -9.07M | -6.65M | -13.9M | -7.04M | -3.17M | -3.52M |
| EPS | -0.08 | -0.11 | -0.11 | -0.12 | -0.11 | -0.05 | -0.03 | -0.04 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 10.9M | 14.3M | 11.4M | 9.11M | 6.54M | 4.05M | 9.25M | 14.3M | 10.4M | 7.52M | 6.67M |
| Total Liabilities | 9.65M | 7.30M | 8.48M | 10.6M | 8.69M | 8.18M | 7.79M | 6.79M | 5.65M | 5.48M | 5.51M |
| Shareholders' Equity | 1.21M | 7.02M | 2.96M | -1.46M | -2.15M | -4.13M | 1.46M | 7.51M | 4.73M | 2.04M | 1.16M |
| Cash & Short-term Investments | 4.99M | 8.41M | 6.31M | 4.14M | 2.42M | 579K | 6.02M | 10.2M | 3.81M | 1.52M | 864K |
| Total Debt | 2.02M | 2.02M | 2.02M | 2.02M | 2.02M | 1.92M | 2.46M | 1.87M | 1.29M | 725K | 238K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.51M | -13.1M | -9.89M | -11.7M | -13.3M | -6.33M | -4.16M | -9.50M | -6.28M | -2.11M | -2.71M |
| Capital Expenditure | 2.67M | 459K | 414K | 336K | 117K | 86.0K | 91.0K | 72.0K | 80.0K | 60.0K | 8.00K |
| Free Cash Flow | -10.2M | -13.5M | -10.3M | -12.0M | -13.4M | -6.42M | -4.25M | -9.57M | -6.36M | -2.17M | -2.72M |
| Ratios | |||||||||||
| ROE | -683.8% | -187.1% | -433.6% | - | - | - | -454.7% | -184.7% | -148.9% | -155.4% | -302.9% |
| ROA | -76.0% | -91.8% | -112.3% | -170.5% | -250.1% | -224.2% | -71.9% | -97.0% | -67.8% | -42.1% | -52.8% |
| Net Profit Margin | - | - | - | - | - | - | -1,571.6% | -60,313.0% | -39,116.7% | -17,600.0% | -14,666.7% |
| Debt to Equity | 1.68x | 0.29x | 0.68x | - | - | - | 1.68x | 0.25x | 0.27x | 0.36x | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Innovation Pharmaceuticals Inc dividends
- Dividend yield
- 33.18%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | USD 86.0K | 0.00 | - |
| 2022 | USD 86.0K | 0.00 | - |
| 2021 | USD 86.0K | 0.00 | - |
| 2020 | USD 9.82M | 0.04 | - |
| 2019 | USD 4.62M | 0.03 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Innovation Pharmaceuticals Inc
Ownership data of Innovation Pharmaceuticals Inc is not available yet.
Innovation Pharmaceuticals Inc company profile
- Company name
- Innovation Pharmaceuticals Inc
- Ticker
- IPIX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- June
- Address
- 301 Edgewater Place, Wakefield, MA, United States, 01880
- Phone
- 978 921 4125
- Website
- ipharminc.com
About Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It offers Brilacidin, a immunomodulatory drug candidate with anti-inflammatory and antimicrobial therapeutic applications. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Innovation Pharmaceuticals Inc management
3- Mr. Leo Ehrlich CPAChairman, CEO, CFO, Principal Accounting Officer & Secretary · born 1958
- Ms. Jane Harness M.S., MPSenior Vice President of Clinical Sciences & Portfolio Management · born 1968
- Mr. Jim BoeheimBusiness Advisor